Centre de Recherche du CHU de Québec, Axe Neurosciences, Québec, QC, Canada.
Département de Médecine Moléculaire, Université Laval, Québec, QC, Canada.
J Huntingtons Dis. 2023;12(1):15-29. doi: 10.3233/JHD-220557.
There is increasing evidence for the presence of pathological forms of tau in tissues of both Huntington's disease (HD) patients and animal models of this condition. While cumulative studies of the past decade have led to the proposition that this disorder could also be considered a tauopathy, the implications of tau in cellular toxicity and consequent behavioral impairments are largely unknown. In fact, recent animal work has challenged the contributory role of tau in HD pathogenesis/pathophysiology. This review presents the supporting and opposing arguments for the involvement of tau in HD, highlighting the discrepancies that have emerged. Reflecting on what is known in other tauopathies, the putative mechanisms through which tau could initiate and/or contribute to pathology are discussed, shedding light on the future research directions that could be considered to confirm, or rule out, the clinical relevance of tau in HD.
越来越多的证据表明，亨廷顿病（HD）患者和该疾病动物模型的组织中存在病理性的 tau 形式。尽管过去十年的累积研究提出，这种疾病也可以被认为是一种 tau 病，但 tau 在细胞毒性和随后的行为障碍中的作用在很大程度上尚不清楚。事实上，最近的动物研究对 tau 在 HD 发病机制/病理生理学中的作用提出了质疑。本综述介绍了 tau 参与 HD 的支持和反对论点，强调了出现的差异。考虑到其他 tau 病的已知情况，讨论了 tau 引发和/或导致病理的可能机制，为今后可能被认为可以证实或排除 tau 在 HD 中的临床相关性的研究方向提供了思路。
